RNAi Therapeutic Market to Grow at a CAGR of 8.8% to reach US$ 1,209.29 million from 2020 to 2027

RNAi Therapeutics Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Molecule Type (Small Interfering RNAs (siRNA) and MicroRNA (miRNA)); Application (Genetic Disorders, Oncology, Neurodegenerative Disorders, Cardiovascular, Respiratory Disorders, Infectious Diseases, Renal Diseases, and Other); Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, and Others); End User (Diagnostic Laboratories, Research and Academic Laboratories, and Hospitals), and Geography

Publication Month: Aug 2020 | Report Code: TIPRE00007157 | No. of Pages: 183 | Category: Biotechnology | Status: Published
Covid

The RNAi therapeutics market  was valued at US$ 618.79 million in 2019and is projected to reach US$  1,209.29 millionby 2027; it is expected to grow at a CAGR of 8.8%from 2020to 2027.

 

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes that are responsible for diseases. At present, the awareness about RNAi is increasing due to its ability to offer target specific mechanism, leading to superior treatment outcomes. The approach is widely utilized for drug development. Increasing investments in RNAi therapy development coupled with growing prevalence of infectious diseases and chronic conditions are anticipated to drive the RNAi Therapeutics market growth during the forecast period.However, high cost involved in the development of RNAi therapies is likely to restraint the growth of the market during the forecast years.

 

Lucrative Regions for RNAi Therapeutics Market

Lucrative Regions for RNAi Therapeutics Market

Get more information on this report :


 

Market Insights

Growing Investments in RNAi Therapies

Continuous R&D activities in RNAi therapeutics have revealed its benefits in tackling a range of chronic disorders such as genetic conditions, renal disorders, neurodegenerative conditions, and oncology. The effectiveness of the outcomes of RNAi therapies is generating investments in the development of new drugs. For instance, in September 2018, Curamir Therapeutics, Inc. received initial financial aid of US$ 10 million from Delos Capital to develop miRNA-based drugs for chemotherapy-resistant cancer. Also, in April 2019, Alnylam Pharmaceuticals Inc. announced its strategic partnership with Regeneron Pharmaceuticals to discover and commercialize RNAi therapeutic platform for the treatment of diseases associated with eye, central nervous system, and liver. The companies have invested about US$ 1 billion in the collaboration. Furthermore, in January 2020, Dicerna Pharmaceuticals, Inc. and Novo Nordisk collaborated to develop RNAi therapies for the treatment of liver diseases and cardiometabolic disorders. Dicerna Pharmaceuticals, Inc. received an upfront payment of ~US$ 175 million from Novo Nordisk for the initiation of the project. Furthermore, according to the terms in partnership, Dicerna Pharmaceuticals, Inc. will receive nearly US$ 25 million annually from Novo Nordisk for the first three years for the development of the product. Such investments help biotech and pharma companies not only launch new products but also increase the number of approved products. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. received an approval from the US Food and Drug Administration (FDA) for its Onpattro infusion therapy used for the treatment of peripheral nerve disease (polyneuropathy). The market players are gaining investments in the R&D of new drugs, therapies, and technologies. These increasing investments in RNAi therapeutics are driving the growth of the market.

 

Molecule Type-Based Insights

Based on molecule type, the RNAi therapeutics market is segmented into small interfering RNAs (siRNA) and microRNA (miRNA). The small interfering RNAs (siRNA) segment held a larger share of the market in 2019. Growth of this segment is attributed to the increasing preference for small interfering RNAs for drug development and growing number of research partnerships. Further, the MicroRNA (miRNA) segment is expected to register higher CAGR in the global RNAi therapeutics market during the forecast period.

 

Global RNAi Therapeutics Market, by Molecule Type– 2019& 2027

Global RNAi Therapeutics Market, by Molecule Type– 2019& 2027

Get more information on this report :


Application-Based Insights

Based on application, the RNAi therapeutics market is segmentedinto oncology, cardiovascular, respiratory disorders, renal diseases, genetic disorders, neurodegenerative disorders, infectious diseases, and others. In 2019, the oncology segment accounted for the largest share ofthe global RNAi therapeutics market owing to increasing preference for RNAi therapies for the treatment of cancer. Moreover, growing number of research collaborations in the field of oncology are also projected to drive the segment growth by 2027. However, cardiovascular disorders segment is estimated to register the highest CAGR in the market during the forecast period.

 

Route of Administration-Based Insights

Based on route of administration, the RNAi therapeutics market is segmented into pulmonary delivery, intravenous injections, intradermal injections, intraperitoneal injections, and others. In 2019, the pulmonary delivery segment accounted for the largest share of the global RNAi therapeutics market. However, intravenous injectionssegment is estimated to register the highest CAGR in the market during the forecast period. Significant number or product launches and higher adoption of intravenous injectionare likely to have a positive impact on the segment growth.

 

End User-BasedInsights

Based on end user, the RNAi therapeutics market is further segmented into research and academic laboratories, hospitals, and diagnostic laboratories. The research and academic laboratoriessegment held the largest share of the market in 2019 and is expected to register the highest CAGR during the forecast period.

 

Strategic Insights

Product launches and expansion strategiesarecommonly adopted by the companies to expand their footprint worldwide and meet the growing demand. This strategy is most commonly adopted by the market players in order to expand its product portfolio.

 

The market players operating in the RNAi therapeutics marketadopted the strategy of product innovation to cater to changing customer demand across the world, which also permits the players to maintain their brand name globally.

 

The global impacts of COVID-19 are being felt across several markets. In case of pharmaceutical industry, supply chain operations are significantly hampered due to the pandemic. However, market players in the RNAi therapeutics are focusing on the development of vaccine with the help of gene silencing technology, which might have a positive impact on the market growth during the forecast period.

 

By Molecule Type

  • Small Interfering RNAs (siRNA)
  • MicroRNA (miRNA)


By Application

  • Oncology
  • Cardiovascular
  • Respiratory Disorders
  • Renal Diseases
  • Genetic Disorders
  • Neurodegenerative Disorders
  • Infectious Diseases
  • Others


By Route of Administration

  • Pulmonary Delivery
  • Intravenous Injections
  • Intradermal Injections
  • Intraperitoneal Injections
  • Others


By End User

  • Research and Academic Laboratories
  • Hospitals
  • Diagnostic Laboratories


RNAi TherapeuticsMarket– By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • UK
    • Spain
    • Rest of Europe
  • Asia Pacific(APAC)
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Rest of APAC
  • Middle East & Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Rest of MEA
  • South and Central America (SAM)
    • Brazil
    • Argentina
    • Rest of SAM

 

Company Profiles

  • Alnylam Pharmaceuticals, Inc.
  • Sanofi
  • Olix Pharmaceuticals, Inc.
  • Glaxosmithkline Plc.
  • Benitec Biopharma
  • Arbutus Biopharma Corporation
  • Silence Therapeutics
  • Rexahn Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc
  • Quark

 

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

1.3.1        Global RNAi Therapeutics Market – By Molecule Type

1.3.2        Global RNAi Therapeutics Market – By Application

1.3.3        Global RNAi Therapeutics Market – By Route of Administration

1.3.4        Global RNAi Therapeutics Market – By End User

1.3.5        Global RNAi Therapeutics market – By Geography

2.             RNAi Therapeutics Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             Global RNAi Therapeutics Market – Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1        North America – PEST Analysis

4.2.2        Europe – PEST Analysis

4.2.3        Asia Pacific – PEST Analysis

4.2.4        Middle East and Africa (MEA) – PEST Analysis

4.2.5        South and Central America (SCAM) – PEST Analysis

4.3       Expert Opinions

5.             RNAi Therapeutics Market– Key Market Dynamics

5.1       Key Market Drivers

5.1.1        Growing Investments in RNAi Therapies

5.1.2        Rising Prevalence of Chronic Conditions and Infectious Diseases

5.2       Market Restraints

5.2.1        High Cost for RNAi Therapy Development

5.3       Market Opportunities

5.3.1        Significant Number of Pipeline Candidates for Strategic Alliances

5.4       Future Trends

5.4.1        Rising Emphasis on RNA Technologies

5.5       Impact analysis

6.             RNAi Therapeutics Market – Global Analysis

6.1       Global RNAi Therapeutics Market Revenue Forecast and Analysis

6.2       Global RNAi Therapeutics Market, By Geography - Forecast and Analysis

6.3       Market Positioning of Key Players

7.             RNAi Therapeutics Market– Molecule Type

7.1       Overview

7.2       RNAi Therapeutics Market Share, Molecule Type, 2019 and 2027 (%)

7.3       Small Interfering RNAs (siRNA)

7.3.1        Overview

7.3.1.1      Small Interfering RNAs (siRNA): RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

7.4       MicroRNA (miRNA)

7.4.1        Overview

7.4.1.1      MicroRNA (miRNA) Market: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.             RNAi Therapeutics Market– Application

8.1       Overview

8.2       RNAi Therapeutics Market Share, Application, 2019 and 2027 (%)

8.3       Genetic Disorders

8.3.1        Overview

8.3.1.1      Genetic Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.4       Oncology

8.4.1        Overview

8.4.1.1      Oncology: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.5       Neurodegenerative Disorders

8.5.1        Overview

8.5.1.1      Neurodegenerative Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.6       Cardiovascular Disorders

8.6.1        Overview

8.6.1.1      Cardiovascular Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.7       Respiratory Disorders

8.7.1        Overview

8.7.1.1      Respiratory Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.8       Infectious Diseases

8.8.1        Overview

8.8.1.1      Infectious Disease: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.9       Renal Diseases

8.9.1        Overview

8.9.1.1      Renal Diseases: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

8.10    Other Disorders

8.10.1     Overview

8.10.1.1    Other Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

9.             RNAi Therapeutics Market Market– Route of Administration

9.1       Overview

9.2       RNAi Therapeutics Market Share, Route of Administration, 2019 and 2027 (%)

9.3       Intradermal Injections

9.3.1        Overview

9.3.1.1      Intradermal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

9.4       Pulmonary Delivery

9.4.1        Overview

9.4.1.1      Pulmonary Delivery: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

9.5       Intravenous Injections

9.5.1        Overview

9.5.1.1      Intravenous Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

9.6       Intraperitoneal Injections

9.6.1        Overview

9.6.1.1      Intraperitoneal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

9.7       Other Route of Administrations

9.7.1        Overview

9.7.1.1      Others: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

10.          RNAi Therapeutics Market Market– End User

10.1    Overview

10.2    RNAi Therapeutics Market Share, End User, 2019 and 2027 (%)

10.3    Diagnostic Laboratories

10.3.1     Overview

10.3.1.1    Diagnostic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

10.4    Research and Academic Laboratories

10.4.1     Overview

10.4.1.1    Research and Academic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027  (US$ million)

10.5    Hospitals

10.5.1     Overview

10.5.1.1    Hospitals: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

11.          RNAi Therapeutics Market – Geographic Analysis

11.1    North America: RNAi Therapeutics Market

11.1.1     Overview

11.1.2     North America: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.3     North America: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.4     North America: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.5     North America: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.6     North America: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.7     North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)

11.1.8     US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.1    US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.8.2    US: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.8.3    US: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.8.4    US: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.8.5    US: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.9     Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.1    Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.9.2    Canada: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.9.3    Canada RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.9.4    Canada: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.9.5    Canada: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.1.10   Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.1 Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.1.10.2 Mexico: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.1.10.3 Mexico: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.1.10.4 Mexico: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.1.10.5 Mexico: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.2    Europe: RNAi Therapeutics Market

11.2.1     Overview

11.2.2     Europe: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11.2.3     Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

11.2.4     Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.2.5     Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.2.6     Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.2.7     Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)

11.2.8     Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.8.1    Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.8.2    Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

11.2.8.3    Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.2.8.4    Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.2.8.5    Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.2.9     UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.9.1    UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.9.2    UK RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

11.2.9.3    UK RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.2.9.4    UK RNAi Therapeutics Market, by Route of Administration– Revenue and Forecast to 2027 (USD Million)

11.2.9.5    UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)

11.2.10   France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.10.1 France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.10.2 France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

11.2.10.3 France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.2.10.4 France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.2.10.5 France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.2.11   Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.11.1 Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.11.2 Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

11.2.11.3 Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.2.11.4 Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.2.11.5 Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.2.12   Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.12.1 Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.2.12.2 Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

11.2.12.3 Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.2.12.4 Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

11.2.12.5 Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.3    Asia Pacific: RNAi Therapeutics Market

11.3.1     Overview

11.3.2     Asia Pacific: RNAi Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11.3.3     Asia Pacific: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.3.4     Asia Pacific: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.3.5     Asia Pacific: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.3.6     Asia Pacific: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.3.7     Asia Pacific: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

11.3.8     China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.8.1    China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.8.2    China: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.3.8.3    China: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.3.8.4    China RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.3.8.5    China RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.3.9     Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.9.1    Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.9.2    Japan: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.3.9.3    Japan: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.3.9.4    Japan RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.3.9.5    Japan RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.3.10   India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.10.1 India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.10.2 India: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.3.10.3 India: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.3.10.4 India RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.3.10.5 India RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.3.11   South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.11.1 South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.11.2 South Korea: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.3.11.3 South Korea: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.3.11.4 South Korea RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.3.11.5 South Korea RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.3.12   Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.12.1 Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.3.12.2 Australia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.3.12.3 Australia: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.3.12.4 Australia RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.3.12.5 Australia RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.4    Middle East & Africa: RNAi Therapeutics Market

11.4.1     Overview

11.4.2     Middle East & Africa: RNAi Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

11.4.3     Middle East & Africa: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.4.4     Middle East & Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027  (USD Million)

11.4.5     Middle East & Africa: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.4.6     Middle East & Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027  (USD Million)

11.4.7     Middle East & Africa: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

11.4.8     Saudi Arabia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.4.8.1    Saudi Arabia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.4.8.2    Saudi Arabia: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.4.8.3    Saudi Arabia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.4.8.4    Saudi Arabia: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.4.8.5    Saudi Arabia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.4.9     UAE: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.4.9.1    UAE: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.4.9.2    UAE: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.4.9.3    UAE RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.4.9.4    UAE: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.4.9.5    UAE RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.4.10   South Africa: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.4.10.1 South Africa: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.4.10.2 South Africa: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.4.10.3 South Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

11.4.10.4 South Africa RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.4.10.5 South Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

11.5    South and Central America: RNAi Therapeutics Market

11.5.1     Overview

11.5.2     South and Central America: RNAi Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

11.5.3     South and Central America: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.5.4     South and Central America: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.5.5     South and Central America: RNAi Therapeutics Market, by Route of Administration, 2018–2027  (USD Million)

11.5.6     South and Central America: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.5.7     South and Central America: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

11.5.8     Brazil: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.5.8.1    Brazil: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.5.8.2    Brazil: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.5.8.3    Brazil: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.5.8.4    Brazil: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.5.8.5    Brazil: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

11.5.9     Argentina: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.5.9.1    Argentina: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

11.5.9.2    Argentina: RNAi Therapeutics Market, by Molecule Type, 2018–2027 (USD Million)

11.5.9.3    Argentina: RNAi Therapeutics Market, by Application, 2018–2027 (USD Million)

11.5.9.4    Argentina: RNAi Therapeutics Market, by Route of Administration, 2018–2027 (USD Million)

11.5.9.5    Argentina: RNAi Therapeutics Market, by End User, 2018–2027 (USD Million)

12.          Impact of COVID-19 Pandemic on Global RNAi Therapeutics Market

12.1    North America: Impact Assessment of COVID-19 Pandemic

12.2    Europe: Impact Assessment of COVID-19 Pandemic

12.3    Asia-Pacific: Impact Assessment of COVID-19 Pandemic

12.4    Rest of World: Impact Assessment of COVID-19 Pandemic

13.          RNAi Therapeutics Market –Industry Landscape

13.1    Overview

13.2    Growth Strategies in the RNAi Therapeutics Market, 2015-2020

13.3    Inorganic Growth Strategies

13.3.1     Overview

13.4    Organic Growth Strategies

13.4.1     Overview

14.          Company Profiles

14.1    Alnylam Pharmaceuticals, Inc.

14.1.1     Key Facts

14.1.2     Business Description

14.1.3     Products and Services

14.1.4     Financial Overview

14.1.5     SWOT Analysis

14.1.6     Key Developments

14.2    Benitec Biopharma

14.2.1     Key Facts

14.2.2     Business Description

14.2.3     Products and Services

14.2.4     Financial Overview

14.2.5     SWOT Analysis

14.2.6     Key Developments

14.3    Sanofi

14.3.1     Key Facts

14.3.2     Business Description

14.3.3     Products and Services

14.3.4     Financial Overview

14.3.5     SWOT Analysis

14.3.6     Key Developments

14.4    GlaxoSmithKline plc.

14.4.1     Key Facts

14.4.2     Business Description

14.4.3     Products and Services

14.4.4     Financial Overview

14.4.5     SWOT Analysis

14.4.6     Key Developments

14.5    Olix Pharmaceuticals, Inc.

14.5.1     Key Facts

14.5.2     Business Description

14.5.3     Products and Services

14.5.4     Financial Overview

14.5.5     SWOT Analysis

14.5.6     Key Developments

14.6    Arrowhead Pharmaceuticals, Inc

14.6.1     Key Facts

14.6.2     Business Description

14.6.3     Products and Services

14.6.4     Financial Overview

14.6.5     SWOT Analysis

14.6.6     Key Developments

14.7    Quark

14.7.1     Key Facts

14.7.2     Business Description

14.7.3     Products and Services

14.7.4     Financial Overview

14.7.5     SWOT Analysis

14.7.6     Key Developments

14.8    Rexahn Pharmaceuticals, Inc

14.8.1     Key Facts

14.8.2     Business Description

14.8.3     Products and Services

14.8.4     Financial Overview

14.8.5     SWOT Analysis

14.8.6     Key Developments

14.9    Silence Therapeutics

14.9.1     Key Facts

14.9.2     Business Description

14.9.3     Products and Services

14.9.4     Financial Overview

14.9.5     SWOT Analysis

14.9.6     Key Developments

14.10 Arbutus Biopharma

14.10.1   Key Facts

14.10.2   Business Description

14.10.3   Products and Services

14.10.4   Financial Overview

14.10.5   SWOT Analysis

14.10.6   Key Developments

15.          Appendix

15.1    About The Insight Partners

15.2    Glossary of Terms

LIST OF TABLES

Table 1.             North America RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)

Table 2.             North America RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 3.             North America RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 4.             North America RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 5.             US RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 6.             US RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 7.             US RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 8.             US RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 9.             Canada RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 10.          Canada RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 11.          Canada RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 12.          Canada RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 13.          Mexico RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 14.          Mexico RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 15.          Mexico RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 16.          Mexico RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 17.          Europe RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 18.          Europe RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 19.          Europe RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 20.          Europe RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 21.          Germany RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 22.          Germany RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 23.          Germany RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 24.          Germany RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 25.          United Kingdom RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 26.          United Kingdom RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 27.          UK: RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million).

Table 28.          UK: RNAi Therapeutics Market, End User – Revenue and Forecast to 2027 (USD Million)

Table 29.          France RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 30.          France RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 31.          France RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 32.          France RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 33.          Spain RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 34.          Spain RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 35.          Spain RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 36.          Spain RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 37.          Italy RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 38.          Italy RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 39.          Italy RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 40.          Italy RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 41.          Asia Pacific RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027 (USD Million)

Table 42.          Asia Pacific RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 43.          Asia Pacific RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 44.          Asia Pacific RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 45.          China RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 46.          China RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 47.          China RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 48.          China RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 49.          Japan RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 50.          Japan RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 51.          Japan RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 52.          Japan RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 53.          India RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 54.          India RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 55.          India RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 56.          India RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 57.          South Korea RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 58.          South Korea RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 59.          South Korea RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 60.          South Korea RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 61.          Incidence, Mortality and Prevalence by cancer site, Australia, 2018

Table 62.          Australia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 63.          Australia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 64.          Australia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 65.          Australia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 66.          Middle East & Africa RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027  (USD Million)

Table 67.          Middle East & Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 68.          Middle East & Africa RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 69.          Middle East & Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 70.          Saudi Arabia RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 71.          Saudi Arabia RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 72.          Saudi Arabia RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027  (USD Million)

Table 73.          Saudi Arabia RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 74.          UAE RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 75.          UAE RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 76.          UAE RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 77.          UAE RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 78.          South Africa RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 79.          South Africa RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 80.          South Africa RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 81.          South Africa RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 82.          South and Central America RNAi Therapeutics Market, by Molecule Type– Revenue and Forecast to 2027  (USD Million)

Table 83.          South and Central America RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027  (USD Million)

Table 84.          South and Central America RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 85.          South and Central America RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027  (USD Million)

Table 86.          Brazil RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 87.          Brazil RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 88.          Brazil RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 89.          Brazil RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 90.          Argentina RNAi Therapeutics Market, by Molecule Type – Revenue and Forecast to 2027 (USD Million)

Table 91.          Argentina RNAi Therapeutics Market, by Application – Revenue and Forecast to 2027 (USD Million)

Table 92.          Argentina RNAi Therapeutics Market, by Route of Administration – Revenue and Forecast to 2027 (USD Million)

Table 93.          Argentina RNAi Therapeutics Market, by End User – Revenue and Forecast to 2027 (USD Million)

Table 94.          Recent Inorganic Growth Strategies in the RNAi therapeutics market

Table 95.          Recent Organic Growth Strategies in the RNAi therapeutics market

Table 96.          Glossary of Terms, RNAi Therapeutics Market

 

LIST OF FIGURES

Figure 1.           RNAi Therapeutics Market Segmentation

Figure 2.           RNAi Therapeutics Market Segmentation, By Region

Figure 3.           RNAi Therapeutics Market Overview

Figure 4.           Small Interfering RNAs (siRNA) Molecule Type Segment Held Largest Share of RNAi Therapeutics Market

Figure 5.           APAC to Show Significant Growth During Forecast Period

Figure 6.           RNAi Therapeutics Market, by Geography (US$ Million)

Figure 7.           Global RNAi Therapeutics Market – Leading Country Markets (US$ Million)

Figure 8.           Global RNAi Therapeutics Market, Industry Landscape

Figure 9.           North America PEST Analysis

Figure 10.        Europe PEST Analysis

Figure 11.        Asia Pacific PEST Analysis

Figure 12.        Middle East and Africa (MEA) PEST Analysis

Figure 13.        South and Central America (SCAM) PEST Analysis

Figure 14.        RNAi Therapeutics Market Impact Analysis of Driver and Restraints

Figure 15.        Global RNAi Therapeutics Market – Revenue Forecast and Analysis – 2019- 2027

Figure 16.        Global RNAi Therapeutics Market – By Geography Forecast and Analysis – 2019- 2027

Figure 17.        Market Positioning of Key Players in Global RNAi Therapeutics Market

Figure 18.        RNAi Therapeutics Market Share, Molecule Type, 2019 and 2027 (%)

Figure 19.        Small Interfering RNAs (siRNA): RNAi Therapeutics Market Market– Revenue and Forecast to 2027  (US$ million)

Figure 20.        MicroRNA (miRNA) Market: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 21.        RNAi Therapeutics Market Share, Application, 2019 and 2027 (%)

Figure 22.        Genetic Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 23.        Oncology: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 24.        Neurodegenerative Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 25.        Cardiovascular Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 26.        Respiratory Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 27.        Infectious Disease: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 28.        Renal Diseases: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 29.        Other Disorders: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 30.        RNAi Therapeutics Market Share, Route of Administration, 2019 and 2027 (%)

Figure 31.        Intradermal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 32.        Pulmonary Delivery: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 33.        Intravenous Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 34.        Intraperitoneal Injections: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 35.        Others: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 36.        RNAi Therapeutics Market Share, End User, 2019 and 2027 (%)

Figure 37.        Diagnostic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 38.        Research and Academic Laboratories: RNAi Therapeutics Market Market– Revenue and Forecast to 2027  (US$ million)

Figure 39.        Hospitals: RNAi Therapeutics Market Market– Revenue and Forecast to 2027 (US$ million)

Figure 40.        North America: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 41.        North America RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 42.        North America: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 43.        US: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 44.        Canada: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 45.        Mexico: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 46.        Europe: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 47.        Europe RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 48.        Europe: RNAi Therapeutics Market, by Country, 2019 & 2027 (%)

Figure 49.        Germany: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 50.        UK: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 51.        France: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 52.        Spain: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 53.        Italy: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 54.        Asia Pacific: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 55.        Asia Pacific RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 56.        China: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 57.        Japan: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 58.        India: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 59.        South Korea: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 60.        Australia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 61.        Middle East & Africa: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 62.        Middle East & Africa RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 63.        Middle East & Africa: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

Figure 64.        Saudi Arabia: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 65.        UAE: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 66.        South Africa: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 67.        South and Central America: RNAi Therapeutics Market, by Key Country – Revenue (2019) (USD Million)

Figure 68.        South and Central America RNAi Therapeutics Market Revenue and Forecast to 2027 (USD Million)

Figure 69.        South and Central America: RNAi Therapeutics Market, by Country, 2018 & 2027 (%)

Figure 70.        Brazil: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 71.        Argentina: RNAi Therapeutics Market – Revenue and Forecast to 2027 (USD Million)

Figure 72.        Impact of COVID-19 Pandemic in North American Country Markets

Figure 73.        Impact of COVID-19 Pandemic in Europe Country Markets

Figure 74.        Impact of COVID-19 Pandemic in Asia-Pacific Country Markets

Figure 75.        Impact of COVID-19 Pandemic in Rest of World Country Markets

Figure 76.        Growth Strategies in the RNAi Therapeutics Market, 2015-2020

 

The List of Companies - RNAi Therapeutics Market

  1. Alnylam Pharmaceuticals, Inc.
  2. Sanofi
  3. Olix Pharmaceuticals, Inc.
  4. Glaxosmithkline Plc.
  5. Benitec Biopharma
  6. Arbutus Biopharma Corporation
  7. Silence Therapeutics
  8. Rexahn Pharmaceuticals, Inc.
  9. Arrowhead Pharmaceuticals, Inc
  10. Quark
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the RNAi therapeutics market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the global RNAI therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPRE00007157
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Frequently Asked Questions

RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes.

The factors that are driving growth of the market are growing investments in RNAitherapies and rising prevalence of chronic conditions and infectious diseases.Moreover, strategic activities by the manufacturersare offering lucrative opportunities for the growth of the market.

The RNAi therapeutics market majorly consists of the players such as Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and Quark amongst others.

Pricing